Harvard scientists have merged stem cell and organ-on-a-chip technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease. The research appears to be a big step forward for personalized medicine because it is working proof that a chunk of tissue containing a patient's specific genetic disorder can be replicated in the laboratory.
The work, published in May 2014 in Nature Medicine, is the result of a collaborative effort bringing together scientists from the Harvard Stem Cell Institute, the Wyss Institute for Biologically Inspired Engineering, Boston Children's Hospital, the Harvard School of Engineering and Applied Sciences, and Harvard Medical School. It combines the organs-on-chips expertise of Kevin Kit Parker, PhD, and stem cell and clinical insights by William Pu, MD.
A release from Harvard explains that using their interdisciplinary approach, the investigators modeled the cardiovascular disease Barth syndrome, a rare X-linked cardiac disorder caused by mutation of a single gene called Tafazzin, or TAZ. The disorder, which is currently untreatable, primarily appears in boys, and is associated with a number of symptoms affecting heart and skeletal muscle function.
The researchers took skin cells from two Barth syndrome patients, and manipulated the cells to become stem cells that carried these patients' TAZ mutations. Instead of using the stem cells to generate single heart cells in a dish, the cells were grown on chips lined with human extracellular matrix proteins that mimic their natural environment, tricking the cells into joining together as they would if they were forming a diseased human heart. The engineered diseased tissue contracted very weakly, as would the heart muscle seen in Barth syndrome patients. The investigators then used genome editinga technique pioneered by Harvard collaborator George Church, PhDto mutate TAZ in normal cells, confirming that this mutation is sufficient to cause weak contraction in the engineered tissue. On the other hand, delivering the TAZ gene product to diseased tissue in the laboratory corrected the contractile defect, creating the first tissue-based model of correction of a genetic heart disease. The release quotes Parker as saying, "You don't really understand the meaning of a single cell's genetic mutation until you build a huge chunk of organ and see how it functions or doesn't function. In the case of the cells grown out of patients with Barth syndrome, we saw much weaker contractions and irregular tissue assembly. Being able to model the disease from a single cell all the way up to heart tissue, I think that's a big advance."
Furthermore, the scientists discovered that the TAZ mutation works in such a way to disrupt the normal activity of mitochondria, often called the power plants of the cell for their role in making energy. However, the mutation didn't seem to affect overall energy supply of the cells. In what could be a newly identified function for mitochondria, the researchers describe a direct link between mitochondrial function and a heart cell's ability to build itself in a way that allows it to contract. "The TAZ mutation makes Barth syndrome cells produce an excess amount of reactive oxygen species or ROSa normal byproduct of cellular metabolism released by mitochondriawhich had not been recognized as an important part of this disease," said Pu, who cares for patients with the disorder. "We showed that, at least in the laboratory, if you quench the excessive ROS production then you can restore contractile function," Pu added. "Now, whether that can be achieved in an animal model or a patient is a different story, but if that could be done, it would suggest a new therapeutic angle." His team is now trying to translate this finding by doing ROS therapy and gene replacement therapy in animal models of Barth syndrome to see if anything could potentially help human patients. At the same time, the scientists are using their human 'heart disease-on-a-chip' as a testing platform for drugs that are potentially under trial or already approved that might be useful to treat the disorder.
"We tried to thread multiple needles at once and it certainly paid off," Parker said. "I feel that the technology that we've got arms industry and university-based researchers with the tools they need to go after this disease." Both Parker and Pu, who first talked about collaborating at a 2012 Stockholm conference, credit their partnership and scientific consilience for the success of this research. Parker asserted that the 'organs-on-chips' technology that has been a flagship of his lab only worked so fast and well because of the high quality of Pu's patient-derived cardiac cells. "When we first got those cells down on the chip, Megan, one of the joint first authors, texted me 'this is working,'" he recalled. "We thought we'd have a much harder fight." "When I'm asked what's unique about being at Harvard, I always bring up this story," Pu said. "The diverse set of people and cutting-edge technology available at Harvard certainly made this study possible." The researchers also involved in this work include: Joint first authors Gang Wang, MD, of Boston Children's Hospital, and Megan McCain, PhD, who earned her degree at the Harvard School of Engineering and Applied Sciences and is now an assistant professor at the University of Southern California. Amy Roberts, MD, of Boston Children's Hospital, and Richard Kelley, MD, PhD, at the Kennedy Krieger Institute provided patient data and samples, and Frdric Vaz, PhD, and his team at the Academic Medical Center in the Netherlands conducted additional analyses. Technical protocols were shared by Kenneth Chien, MD, PhD, at the Karolinska Institutet.
Kevin Kit Parker, PhD, is the Tarr Family Professor of Bioengineering and Applied Physics in Harvard's School of Engineering and Applied Sciences, a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering, and a Principal Faculty member of the Harvard Stem Cell Institute. William Pu, MD, is an Associate Professor at Harvard Medical School, a member of the Department of Cardiology at Boston Children's Hospital, and an Affiliated Faculty member of the Harvard Stem Cell Institute. George Church, PhD, is a Professor of Genetics at Harvard Medical School and a Core Faculty member of the Wyss Institute of Biologically Inspired Engineering. The work was supported by the Barth Syndrome Foundation, Boston Children's Hospital, the National Institutes of Health, and charitable donations from Edward Marram, Karen Carpenter, and Gail Federici Smith.
See the rest here:
Stem Cells Make Heart Disease-on-a-Chip
- Research Assistant - Department of Obstetrics and Gynaecology job with NATIONAL UNIVERSITY OF SINGAPORE | 239606 - Times Higher Education (THE) - December 24th, 2020
- Getting to the root of why hair goes gray - messenger-inquirer - December 24th, 2020
- How the COVID Virus Induces Inflammation, Cytokine Storm and Stress in Infected Lung Cells - SciTechDaily - December 24th, 2020
- Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health - News@UofT - December 22nd, 2020
- 2020 in Neuroscience, Longevity, and AIand What's to Come - Singularity Hub - December 22nd, 2020
- Updated Findings Show Continued Efficacy for CAR T-Cell Therapy in Heavily Pretreated Myeloma - Targeted Oncology - December 14th, 2020
- Cell Isolation/ Separation Market worth $15.0 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire - December 14th, 2020
- Cord blood banks sell parents on promising stem cell research, but with no guarantees - The Arizona Republic - December 8th, 2020
- Procyon Technologies LLC and Novo Nordisk A/S to Collaborate on the Development of a Stem-Cell Based Therapy for Type 1 Diabetes - PRNewswire - December 8th, 2020
- Genetic engineering transformed stem cells into working mini-livers that extended the life of mice with liver disease - The Conversation US - December 8th, 2020
- Hadassah Medical Center and Neurogenesis Announce Groundbreaking Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01... - December 8th, 2020
- Worldwide Cell Culture Industry to 2025 - Featuring Thermo Fisher Scientific, Corning Incorporated and Eppendorf Among Others - GlobeNewswire - December 8th, 2020
- The cell culturemarket is projected to reach USD 33.1 billion by 2025 from USD 19.0 billion in 2020, at a CAGR of 11.8% - GlobeNewswire - December 8th, 2020
- Treatment with Investigational LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe... - December 8th, 2020
- New DARZALEX (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma - BioSpace - December 8th, 2020
- Anatomy of a vaccine: What it takes to create a safe, effective COVID shot - University of California - December 8th, 2020
- Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine - Newswise - December 3rd, 2020
- UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies - UCLA Newsroom - December 3rd, 2020
- Human Embryonic Stem Cells Market in Global : Current and the Future Trends: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc - The... - December 3rd, 2020
- Possible Role for Comprehensive Molecular ProfilingBased Treatment Selection in Newly Diagnosed AML, Study Suggests - Cancer Therapy Advisor - December 3rd, 2020
- Nobel Prize history from the year you were born - Herald & Review - December 3rd, 2020
- 4D hires a trio of area heads as it ramps up its gene therapy pipeline - FierceBiotech - December 3rd, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - GlobeNewswire - December 1st, 2020
- ONLINE: The UW Now - Isthmus - December 1st, 2020
- Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study - PRNewswire - December 1st, 2020
- Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - GlobeNewswire - December 1st, 2020
- Exploring the Challenges and Opportunities of Harvesting CTCs - Technology Networks - December 1st, 2020
- Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells - PR Web - November 18th, 2020
- Stem Cells Market Detailed Analysis by On-going Trends, Prominent Size, Share, Sales and Forecast to 2025 - PRnews Leader - November 18th, 2020
- Study reveals how smoking worsens SARS-CoV-2 infection in the airways - UCLA Newsroom - November 18th, 2020
- Cell Expansion Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights -... - November 18th, 2020
- University of Alberta research team poised to cure diabetesagain - The Post - Ontario - November 18th, 2020
- Comprehensive Report on Stem Cell Assay Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Bio-Techne Corporation, Promega... - November 18th, 2020
- Asia Pacific ultra-low temperature freezer market is anticipated to reach US$ 159.04 million by 2027 from US$ 109.02 million in 2019 - GlobeNewswire - November 18th, 2020
- California's Stem Cell Agency Will Get A Funding Boost From Prop 14. Here's A Look At Its History. - Capital Public Radio News - November 16th, 2020
- Gene-edited monkey embryos give researchers new way to study HIV cure - University of Wisconsin-Madison - November 16th, 2020
- Lineage Cell Therapeutics Proudly Supports Patients' Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14 -... - November 16th, 2020
- ExCellThera to establish stem cell bioproduction facility creating up to 150 jobs thanks to Government of Canada support - Canada NewsWire - November 16th, 2020
- Stanford coach's quest to save his brother: 'God, I hope this works' - Scope - November 16th, 2020
- The story of mRNA: From a loose idea to a tool that may help curb Covid - STAT - November 16th, 2020
- Sobi's Gamifant receives final rejection from CHMP for primary HLH - PMLiVE - November 16th, 2020
- Meeting Agenda Focuses on Increased Applications of Cellular Therapies in Hematologic Cancers - Targeted Oncology - November 16th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 12th, 2020
- Regenerative Medicine Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast till 2026 - Illadel Graff Supply - November 12th, 2020
- Leading Human Immunology and Infectious Disease Experts to Join UM School of Medicines Institute of Human Virology - Newswise - November 12th, 2020
- UB researcher narrows time window for administering specific treatment to infants with Krabbe disease - UB Now: News and views for UB faculty and... - November 12th, 2020
- FibroGenesis Announces the Filing of its 250th Patent for Fibroblast Cell Therapy Platform - PRNewswire - November 12th, 2020
- FROM THE LABS: Hispanic Heritage Spotlight: Interview with Dr. Nino Rainusso - Baylor College of Medicine News - November 12th, 2020
- Protective protein could help keep blood young and healthy - New Atlas - November 12th, 2020
- Global Stem Cell Therapy Market Growth Factor with Regional Forecast, Segmentation, Investment Opportunities, Industry Research and End User Analysis... - November 9th, 2020
- Worldwide Regenerative Medicine Industry to 2025 - Featuring Allergan, Amgen and Baxter International Among Others - PRNewswire - November 9th, 2020
- Her favorite part of research was the patients, so she switched to primary... - Bothell-Kenmore Reporter - November 9th, 2020
- Regenerative Medicine Stem Cells Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2019 - KYT24 - November 5th, 2020
- How the Election Could Affect Health Care and Drug Policy - Scientific American - November 5th, 2020
- A Biden Win and Republican Senate Might Lead to Gridlock on Health Issues - Kaiser Health News - November 5th, 2020
- Angelika Amon, cell biologist who pioneered research on chromosome imbalance, dies at 53 - MIT News - October 30th, 2020
- USC biological imaging innovator elected to National Academy of Medicine > News > USC Dornsife - USC Dornsife College of Letters, Arts and... - October 24th, 2020
- Repurposing and Combining Drugs An Effective Cancer Treatment Strategy - Technology Networks - October 24th, 2020
- Rates of Invasive Pulmonary Aspergillosis in ICU Patients With Influenza Far Lower Than Previously Thought - Contagionlive.com - October 24th, 2020
- Stem Cell and Regenerative Therapy Market Report to Describe Major Companies and Their Strategies (2019-2024) - PRnews Leader - October 23rd, 2020
- Baby Gets Early Stem Cell Transplant to Treat Rare Disease Thanks to Newborn Screening - University of Michigan Health System News - October 23rd, 2020
- Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn - GlobeNewswire - October 23rd, 2020
- Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine's 2021 Board of Directors - GlobeNewswire - October 23rd, 2020
- Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech - October 23rd, 2020
- Five Penn faculty elected to the National Academy of Medicine - Penn Today - October 21st, 2020
- Vor Biopharma Appoints Matthew R. Patterson to its Board of Directors - BioSpace - October 21st, 2020
- Harvard Business School and Harvard's Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from Chris and Carrie Shumway to... - October 20th, 2020
- Human Embryonic Stem Cells (HESC) Industry Research Report, Growth Trends and Competitive Analysis 2020-2027: ESI BIO, Thermo Fisher, BioTime,... - October 20th, 2020
- Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development - PRNewswire - October 20th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Potential Growth, Competitive Landscape and Development of Industry by 2025 Wall Street... - October 20th, 2020
- Regenerative Medicine Market 2020 Industry Insights by Share, Emerging Trends, Regional Analysis, Segments, Prime Players, Drivers, Growth Factor and... - October 20th, 2020
- The untapped market of cord blood banking - The Malaysian Reserve - October 15th, 2020
- Singapore invents digitized optimization of culture conditions for cell therapy - BSA bureau - October 15th, 2020
- Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease... - October 15th, 2020
- U of T's Medicine by Design invests $1 million to advance new ideas in regenerative medicine - News@UofT - October 10th, 2020
- Proposition 14 would authorize state to borrow $5.5 billon for stem cell research - KESQ - October 10th, 2020
- AIVITA Biomedical's Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science - PRNewswire - October 10th, 2020
- Regenerative Medicine Market | Increasing Prevalence of Chronic Diseases to Boost the Market Growth | Technavio - Business Wire - October 10th, 2020
- University of Wisconsin Researchers Use Stem Cells to Treat Parkinson's - Gilmore Health News - October 10th, 2020
- Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire - October 10th, 2020